Synthesis and structure-activity relationship studies for hydantoins and analogues as voltage-gated sodium channel ligands

被引:35
作者
Zha, CX
Brown, GB
Brouillette, WJ [1 ]
机构
[1] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Psychiat & Behav Neurosci, Birmingham, AL 35294 USA
关键词
D O I
10.1021/jm040077o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We previously developed a preliminary 3-D QSAR model for the binding of 14 hydantoins to the neuronal voltage-gated sodium channel; this model was successful in designing,an effective non-hydantoin ligand. To further understand structural features that result in optimum binding. here we synthesized a variety of compound classes and evaluated their binding affinities to the neuronal voltage-gated sodium channel using the [H-3]-batrachotoxinin A 20-a-benzoate ([H-3]BTX-B) binding assay. In order to understand the importance of the hydantoin ring for good sodium channel binding, related non-hydantoins such as hydroxy amides, oxazolidinediones, hydroxy acids, and amino acids were included. Two major conclusions were drawn: (1) The hydantoin ring is not critical for compounds with long alkyl side chains, but it is important for compounds with shorter side chains. (2) Relative to Khodorov's pharmacophore. which contains two hydrophobic regions, a third hydrophobic region may enhance binding to provide nanomolar inhibitors.
引用
收藏
页码:6519 / 6528
页数:10
相关论文
共 52 条
[41]  
SHELDON RS, 1994, J PHARMACOL EXP THER, V268, P187
[42]  
TAYLOR CP, 1997, ADV PHARMACOL, V39, P447
[43]   Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles [J].
Unverferth, K ;
Engel, J ;
Höfgen, N ;
Rostock, A ;
Günther, R ;
Lankau, HJ ;
Menzer, M ;
Rolfs, A ;
Liebscher, J ;
Müller, B ;
Hofmann, HJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (01) :63-73
[44]  
Urenjak J, 1996, PHARMACOL REV, V48, P21
[45]   Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide [J].
Vamecq, J ;
Lambert, D ;
Poupaert, JH ;
Masereel, B ;
Stables, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3307-3313
[46]  
Waxman SG, 2000, J REHABIL RES DEV, V37, P517
[47]  
Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO
[48]  
2-G
[49]  
WAXMAN SG, 2001, NEUROLOGY, V236, P5
[50]  
Wood J N, 2001, Curr Opin Pharmacol, V1, P17, DOI 10.1016/S1471-4892(01)00007-8